Allison Dorval
2021 - Verve Therapeutics
In 2021, Allison Dorval earned a total compensation of $3.3M as Chief Financial Officer at Verve Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $22,890 |
|---|---|
| Option Awards | $3,014,145 |
| Salary | $39,545 |
| Stock Awards | $249,375 |
| Other | $769 |
| Total | $3,326,724 |
Dorval received $3M in option awards, accounting for 91% of the total pay in 2021.
Dorval also received $22.9K in non-equity incentive plan, $39.5K in salary, $249.4K in stock awards and $769 in other compensation.
Rankings
In 2021, Allison Dorval's compensation ranked 4,019th out of 12,405 executives tracked by ExecPay. In other words, Dorval earned more than 67.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,019 out of 12,405 | 68th |
Division Manufacturing | 1,646 out of 5,494 | 70th |
Major group Chemicals And Allied Products | 681 out of 2,369 | 71st |
Industry group Drugs | 604 out of 2,090 | 71st |
Industry Pharmaceutical Preparations | 423 out of 1,537 | 73rd |
Source: SEC filing on April 29, 2022.
Dorval's colleagues
We found two more compensation records of executives who worked with Allison Dorval at Verve Therapeutics in 2021.